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Tumour markers are important in the diagnosis and monitoring of many tumours. This study tested the hypothesis that an oncofoetal
protein, foetal haemoglobin (HbF) is a potential tumour marker in embryonic tumours, useful for management. An
immunohistochemical investigation of HbF blood cell (Fc) distribution was carried out in tumours and in bone marrow samples
from 83 children and 13 adults with various embryonic tumours (blastomas), and in bone marrow samples of 24 leukaemia patients.
In the three, main blastoma types, nephroblastoma (Wilms’ tumour), neuroblastoma and retinoblastoma, where all the patients,
except two, were children, around 80% of the tumour samples had Fc within proliferating blood vessels and spaces between tumour
cells. In parallel, clusters of Fc, mostly F-erythroblasts (Feb), were distributed in the bone marrow of some of those patients and in the
bone marrow of 79% of the leukaemia patients. Foetal haemoglobin, as well as being a potential prognostic cancer marker, is a
potential indicator of DNA hypomethylation implicated in the development of these tumours, as well as in others previously noted
for the presence of HbF.
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Elevated concentrations of foetal haemoglobin (HbF) are common
in the predominant kinds of solid tumours as well as in
haematological malignancies (Wolk et al, 1991, 1999). In preliminary
follow-up studies conducted on childhood leukaemia (Rautonen and
Siimes, 1990), in myelodysplastic syndrome (Reinhardt et al, 1998)
and in non-Hodgkin’s lymphoma (Wolk and Newlands, 2004), HbF
has been evaluated as a valid prognostic parameter, which should be
considered in the management of the disease. There is evidence that
HbF inducing growth factors are raised in cancer patients, including
stem cell growth factor (CSF) and interleukin-3 in the serum of
colorectal cancer patients (Mroczko et al, 2003), and a growth factor
found in the bone marrow of patients with myelodysplastic
syndrome (Choi et al, 2002). However, the mechanisms for renewal
of globin g-chain gene expression in cancer patients are yet not clear.
Foetal haemoglobin in most cases is not a product of the tumour
cells. Foetal haemoglobin expression by the blood cells surrounding
the tumour appears to be induced under the conditions of
malignancy. Defining these conditions might contribute to the
understanding of carcinogenesis at its basic levels. In this respect, we
note that DNA hypomethylation (DNhpom) at CpG dinucleotides
(cytosine nucleotide found adjacent to guanine nucleotide) is an
example of an epigenetic process implicated in the promotion of
carcinogenesis (Ehrlich, 2005), as well as in the activation of globin
g-chain gene expression (Atweh et al, 2003; Lavelle, 2004). For
example, DNhpom was proved experimentally to promote hepato-
cellular carcinogenesis (Yamada et al, 2005) and T-cell lymphoma
(Gaudet et al, 2003), and to correlate with recurrence in
hepatocellular carcinoma (Itano et al, 2002). In parallel, a DNA
hypomethylating cytidine analogue drug given to lung cancer
patients (Carr et al, 1987) and to patients with sickle cell disease
(Saunthararajah et al, 2004) increased their HbF concentrations. In
the sickle cell patients, HbF rose to 22% (normal level iso1%).
Hence, DNhpom agents might promote neoplasia in prospective
tumour cells simultaneously with reactivation of HbF gene
expression in erythrocytes precursors, residing inside the tumour
tissues or in haematopoietic tissues of the same organism. This
hypothesis is not impaired by the evidence for inactivation of
tumour suppressing genes by DNA hypermethylation, since
hypermethylation is specific for unique genomic sites while at the
same time global DNA is hypomethylated (Ehrlich et al,2 0 0 2 ;
Brothman et al, 2005; Ehrlich, 2005). By that ambiguity, the use of
DNA demethylating agents as therapeutic anticancer regiment might
contribute to carcinogenesis (Ehrlich, 2005). By establishing the
association between carcinogenesis and HbF via DNhpom, detection
of HbF might contribute to therapeutic strategies, and to the alerting
of hypomethylating agents in the environment, suspected as
carcinogenic hazards. The first indication for a possible link
between DNhpom in tumour tissue (in the tissues of colorectal
adenocarcinoma) and DNhpom of the g-globin gene came by
demonstrating hybridization between the two sources of DNA
(Feinberg and Vogelstein, 1983). Since then, DNhpom has
been found in a large variety of tumour tissues, including
leukaemia (Yoshida et al, 2004), prostate (Brothman et al, 2005),
breast (Van den Eyden et al, 2005), urinary bladder (Nakagawa
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set al, 2005) and others, most of them known for elevated HbF.
Another group of solid tumours notable for DNhpom, is embryonic
tumours (blastomas), which are most common in children.
The aim of this study was to investigate the presence of F-cells in
blastoma-related tumours by the use of immunohistochemistry. In
this way, conditions inducing HbF expression can be related
locally to the tumour tissue, rather than to the whole organism, as
in our study of colorectal tumours, where we detected local
development of F-cells (Wolk et al, 2006).
Our study included Wilms’ tumour (nephroblastoma), neuro-
blastoma, retinoblastoma, childhood leukaemia, rhabdomyosarcoma
and others, all of which originate from primordial embryonic cells,
including the embryonic neural crest as the presumed source of
neuroblastoma, Ewing’s sarcoma, medulloblastoma and rhabdo-
myosarcoma. All have similar morphology, with uniform,
primitive embryonic, blastoma cells. Some of them are reported
to share the same oncogenes, as WT1 in Wilms’ tumour (Maiti
et al, 2000), in retinoblastoma (Wagner et al, 2002) and in acute
myeloid leukaemia (King-Underwood et al, 1996), and RB1 in
retinoblastoma (Sanchez et al, 2000), neuroblastoma (Markaki
et al, 2001), childhood leukaemia (Markaki et al, 2001) and Ewing’s
sarcoma (Cope et al, 2001). We evaluated HbF as a cancer marker
in those diseases by examining the histological distribution of
F-cells in the tumours and bone marrow of those patients, noting
their concentrations and locations.
MATERIALS AND METHODS
Participants
The study was conducted in two institutions: (1) Pathology Group,
Institute of Cell and Molecular Sciences, The Royal London
Hospital, England and (2) Department of Histology and Embry-
ology, Poznan University of Medical Sciences, Poland. The
programme of research including studies on archival and stored
materials was approved by The East London and City Health
Authority Research Ethics Committee and by the Poznan
University of Medical Sciences, Department of Paediatric Oncol-
ogy, Haematology and Transplantology, Ethics Committee.
Immunohistochemical staining
We used the peroxidase avidin–biotin method with an affinity
purified anti-HbF (Wolk et al, 2004). All the reagents used, as well
as the procedures of immunostaining confirmed by control
staining, were as described in our previous work (Wolk et al,




The study included examination of histological tumour and bone
marrow specimens of the following diseases: nephroblastoma
(n¼24), leukaemia (n¼24), retinoblastoma (n¼18), neuroblas-
toma (n¼17), rhabdomyosarcoma (n¼14), medulloblastoma
(n¼11), Ewing’s sarcoma (n¼2), hepatoblastoma, neurofibroma
and glioblastoma (n¼1 for each). All these patients, except
those with leukaemia and medulloblastoma, were predominantly
children.
Foetal haemoglobin blood cells (Fc) comprised mature erythro-
cytes (Fer) and nucleated erythroblasts (Feb), which could
sometimes be binucleated or in mitosis. Foetal haemoglobin blood
cells were identified and were distributed in blood vessels or free in
tumour tissues. In the blood vessels their concentrations were
Figure 1 Nephroblastoma. (A) Large blood vessel in tumour tissue, containing 20% Fer. Calibration bar, 50mm. (B) Tubular differentiating area with
proliferating blood vessels full of Fc. Calibration bar, 50mm. (C) Fc within glomeruloid body. Arrow indicates one Feb. Calibration bar, 25mm.
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s0–100%. They could be distributed either randomly in the blood
vessels, in most of the cases not exceeding 50% of the total blood
cells (Figure 1A), or at 100% inside proliferating, closely aligned
blood vessels (Figures 1B and 2A). In the following tables, cases
classified as (1) ‘low-percent Fer’ (Ferþ), were those with 0–30%
Fc per one blood vessel, in which usually no more than 20% of the
vessels contained Fc; (2)‘high-percent Fer’ (Ferþþ) were those
with 430–100% Fc per one blood vessel, where usually 30–100%
of the blood vessels contained Fc. Close to the proliferating blood
vessels, there were packed free extravascular clusters of Fc,
including many Feb, as in proliferation centres (Figure 2B).
Usually Fc were also observed infiltrated among the tumour cells
and congested in large areas of necrosis or haemorrhage (Figures
3A and B). In bone marrow, F-cells were observed in dense clusters
of 3–50 cells distributed through the whole section (Figures 4
and 5).
The scarce cases treated by chemotherapy prior to our
examination were noted in the tables of results.
Nephroblastoma
Table 1 summarizes the immunohistochemical distribution of Fc
in 24 patients with tumours. Foetal haemoglobin blood cells were
detected in 19 (79%) of these patients, all of them children aged 1–
14 years (Table 1, numbers 1–9, 14–23). Control specimens
included one normal kidney (Table 1, number 22), seven normal
Figure 2 Retinoblastoma. (A) Proliferating blood vessels full of Fc. Thirty
percent are (nucleated) Feb, two of which are indicated by arrow.
Calibration bar, 50mm. (B) A condensation of extravascular Fc (indicated
by arrow) between the two blood vessels of Fc. Calibration bar, 50mm.
Figure 3 (A) Infiltrating Fc (orange immunostained) in neuroblastoma of
the brain. To the left is a brain tissue free of Fc. Calibration bar, 50mm. (B)
Neurofibroma; an example of congested Fc in a necrotic area (bellow) and
Fc infiltrated into tumour tissue (above). Calibration bar, 50mm.
Figure 4 Rhabdomyosarcoma. Bone marrow with a network forming
clusters of Fer and Feb. Arrows indicate two Feb in mitosis. Calibration bar,
50mm.
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skidney tissues adjacent to a removed tumour (Table 1, numbers
10–13, 15, 16, 24 ) and three kidney tissues of patients with
glomerulonephritis (Table 1, numbers 31–33). No Fc were
observed in these controls, except one case (Table 1, number
10). Ten patients (Table 1, numbers 1–10) were followed up until
the present time. However, no correlation could be found between
the last clinical stage reported and the Fc distribution. All the
tumours were of three-phase nephroblastoma, including all the
three cellular components, namely: blastoma cells, mesenchyme
and epithelial cells forming tubular elements. Foetal haemoglobin
blood was found in each of these components, including tubular
structures (Table 1, numbers 9, 10, 23) and glomeroid bodies
(Table 1, number 7, 9; Figure 1C), as well as in the blood vessels
(Table 1, numbers 1–8, 10, 15, 16, 17, 19, 20, 21; Figure 1A)
Congested Fc were very common in large necrotic and haemo-
rrhagic areas, or between tumour cells. Evidence was also found
for proliferating blood vessels full of Fc (Table 1, numbers 2, 3, 8;
Figure 1B).
Neuroblastoma
The results are summarized in Table 2. Tumour specimens were
examined in 16 children, 2/12–14 years old and one adult. Twelve
of them (75%) were Fc positive. Foetal haemoglobin blood cells,
mainly Fer, were infiltrated among the tumour cells (as in Figures
3A and B) and randomly distributed inside blood vessels. No F-
cells were found in ganglioneuroma (Table 2, number 5) or in
brain tissue adjacent to the tumour tissue (Table 2, number 6;
Figure 3A). No correlation could be found between the clinical
condition and the distribution of Fc. In the bone marrow with
metastases, high concentrations of Feb were observed in one
patient (Table 2, number 14), while three other bone marrow
samples were negative.
Retinoblastoma
The results are summarized in Table 3. Here again all patients
were very young infants, most of them 3 years and younger.
Eleven (78.6%) of the 14 tumour specimens were Fc positive.
Non-metastatic bone marrow specimens from three out of
four other patients were strongly positive for Fc, mostly Feb.
The expression of foetal haemoglobin and the percentages of Feb
were very prominent, exceeding all other tumour types examined
here.
Some of the Feb were binucleated or in mitosis. We noted here
the high rate of proliferating Fc in regenerating blood vessels and
in free cell clusters (Table 3, numbers 1–4; Figures 2A and B)
Rhabdomyosarcoma
The results are summarized in Table 4. Eight (89%) of the
nine tumour specimens were Fc positive. Tumour specimens
were from seven children, 1–8 years old, and two adults. In
tumour blood vessels, the F-cells were randomly distributed. Free
Fc were distributed in tumour tissues as in the groups above. In
bone marrow specimens from two of five patients, there were
clusters of Fc, and high-rate Feb mitosis was noted in one of them
(Figure 4).
Medulloblastoma
All specimens were from tumour in the cerebellum. As described
in Table 5, five patients were children 5–15 years old and six other
were young adults. Six of the 11 patients were Fc positive, with the
characteristic distribution as above.
Leukaemia
A list of Fc positive and negative cases is shown in Table 6. Bone
marrow specimens were examined from 24 patients; 19 (79%) of
them were Fc positive. Seven patients were boys and girls aged
2–14 years. The remaining 17 adult patients were aged between 31
and 83 years. Our initial aim was to examine childhood leukaemia
because it is considered as leukoblastoma (van den Berg, 2002).
However, our results indicated that the incidence and magnitude
of Fc distribution were the same for children and adults. There was
also no difference with regards to the type of leukaemia. Foetal
haemoglobin blood cells were distributed through the whole
sections of the bone marrow as cluster of 3 to 50 cells, most of
them Feb. All of them were strongly stained (þþþþþ), as
shown in Figures 5A and B.
Ewing’s sarcoma One tumour specimen, from the temporal bone
of a 60-year-old man, had Fc distributed at 10–50% in part of the
blood vessels and in necrotic areas. About 1/4 of these Fc were Feb.
Another sacral tumour from a 2-year-old boy had a few fine blood
vessels with 100% Fer.
Neurofibroma In a tumour specimen from a cyst in the leg of
1-year-old boy, we observed Fc cells infiltrating among tumour
cells and in adjacent necrotic areas, where some were Feb, as
shown in Figure 3B.
Figure 5 Leukemia. (A) Bone marrow from hairy cell leukaemia with a
large concentration of Feb and other dispersed. Feb and Fer. Calibration
bar, 50mm. (B) A cluster of Feb in a bone marrow from CML. Calibration
bar, 25mm.
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sGlioblastoma Tumour specimen from the brain of a 52-year-old
woman consisted of blastoma-like cells infiltrated by Fer. The
adjacent brain tissue was free of Fc.
Hepatoblastoma In a bone marrow specimen from a 2-year-old
girl, we observed Fc, most of them Feb, distributed as foci and as
single cells.
DISCUSSION
As described in the results, F-cells (Fc) were distributed in various
patterns inside the embryonic tumour tissues. Foetal haemoglobin
blood cells probably originate in the bone marrow and, delivered
by circulation, were found randomly at 0–50% in the main blood
vessels (Figure 1A). However, Fc including Feb comprised up to
Table 2 The distribution of F-cells immunohistochemically detected in neuroblastoma
F-cells features (1) Checked in tumour tissues
No Gender
Age
(years) Clinical parameters BV NB GN BR Staining grade
1 Female 14 Stage IV adrenal NB with mets to bone marrow, died Fer++ No Fc ( )(  ) (++)
2 Male 4 Stage IV, adrenal NB with mets to bone marrow, died ( ) Fer ( )(  ) (++++)
3 Male 9 Stage III in the mediastinum, remission, relapse, died No Fc ( )
4 Female 13 Stage III, remission relapse, remission Fer++ Fer ( )(  ) (+++)
5 Male 1 Stage IV neuroblastoma and ganglioneuroma in
adrenal tissue
No Fc Fer No Fc ( ) (+++)
6 Male 5 Stage IV brain (olfactory area) NB ( ) Fer,Feb. ( ) No Fc (++++)
7 Male 4 Adrenal NB, mostly necrotic tissue ( ) Fer ( )(  ) (+++)
8 Male 2 Stage IV, abdominal mass NB Fer+ No Fc ( )(  ) (+++)
9 Male 1 Stage IV adrenal NB. Chemotherapy (+) No Fc Fer ( )(  ) (++++)
10 Male 11 Spontaneously regressed NB in mediastinum No Fc Fer ( )(  ) (+++)
11 Male 1 Undifferentiated abdominal NB Fer+ No Fc ( )(  )( + )
12 Male 67 No comments available No Fc Fer ( )(  )( + )
13 Male 2/12 Same as above No FC ( )
14 Female 5 Stage IV metastatic NB to BM (2) Checked in bone marrow
Clusters of 4–20 Fc, mainly Feb, throughout the whole area
(+++++)
15 Male 3 Adrenal non metastatic NB No Fc ( )
16 Female 3 Stage IV adrenal NB metastatic to bone No Fc ( )
17 Male 2 Same as above No Fc ( )
Abbreviations: ( ), tissue not present in section; BV, blood vessels; BR, normal brain tissue; Fc, F-cell; Feb, F-blasts; Fer, F-erythrocytes; Fer+, low percent of Fer; Fer++, high
percent of Fer; GN, ganglioneuroma; NB, neuroblastoma.
Table 1 The distribution of F-cells immunohistochemically detected in nephroblastoma
F-cells features
No. Gender Age (years) Clinical parameters BV PBV TC GL TB NK Staining grade
1 Female 6 Stage IV, pulmonary metastases, died Fer++ ( ) Fer ( )(  ) (+++)
2 Female 7 Stage III, died Fer++ Fer Fer (+++++)
3 Female 8 Stage III, died Fer No Fc (+++)
4 Male 5 Stage IV, pulmonary metastases, remission, relapse,
remission
Fer+ ( )N o F c (  )(  )( + )
5 Male 4 Stage III, remission Fer++ ( ) Fer,Feb ( )(  ) (+++++)
6 Male 8 Stage III, remission Fer++ ( )( + + )
7 Female 13 Stage III, remission Fer,Feb+ Fer,Feb Fer,Feb (+++++)
8 Female 11 Stage III ,remission Fer++ Fer No Fc (+++++)
9 Male 3 Stage III, relapse and remission ( )(  ) No Fc Fer Fer (++++)
10 Male 2 Stage III, remission, adjacent NK Fer+ ( )N o F c (  ) Fer o(+)
11–13 Females 4, 5, 9 Stage II, remission, adjacent NK No Fc ( )
14 Male 2 Metastatic stage IV, lung with metastases.
Chemother(+)
( )(  ) Fer (++++)
15 Male 6 Stage III+adjacent NK Fer+ ( ) No Fc No Fc (+++)
16 Female 1 Stage III+adjacent NK Fer+ ( ) No Fc No Fc (+++)
17 Male 1 Stage II Fer+ Feb ( )(  ) (+++++)
18 Male 7 Stage II ( )(  ) Fer ( )(  ) (+++)
19 Female 2 Stage I Fer+ ( ) Feb ( )(  )
20 Female 3 Stage I Fer+ ( ) Fer ( )(  ) (+++)
21 Male 1 Stage I Fer+ ( ) Fer ( )(  ) (+++)
22 Female 4 Stage I+counterpart NK. Chemoth(+) ( )(  ) Fer ( )(  ) No Fc (+++)
23 Male 14/12 Stage I ( )(  )N o F c (  ) Fer (+++)
24 Female 1 Stage I adjacent NK. Chemoth(+) No Fc ( )
25–29 3 female 2 male 2, 3, 5 17, 22 Stage I (4), stage II (1) No Fc ( )
30–32 1 female 2 male 4, 7, 9 Kidney of glomerulonephritis No Fc ( )
Abbreviations: ( ), tissue not present in the section; BV, normal blood vessels; Fc, F-cells; Feb, F-erythroblasts; Fer, F-erythrocytes; Fer+, low percent of FER; Fer++, high percent
of Fer; GL, glomeruloid bodies; NK, normal kidney; PBV, proliferating blood vessels; TB, tubular structures; TC, undifferentiated tumour cells.
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s100% of the contents of proliferating blood vessels and as packed
free clusters (Figures 2A and B) could have originated in the
tumour tissue. It seems therefore that there are two sources of Fc.
One is in the bone marrow leading to elevated whole-blood HbF
concentration, and the other is in the tumour tissue leading to
elevated plasma HbF concentration. A support for this assumption
is found in our previous works showing that plasma HbF and
whole-blood HbF are two independent indicators in many kinds of
cancer (Wolk et al, 1999). One of these cancers was non-Hodgkin’s
lymphoma, in the patients of which we have immunohistochemi-
cally detected Fc in lymph nodes and in bone marrow (Wolk et al,
2004), which respectively might have been the sources for (1)
plasma HbF and (2) whole-blood HbF. We have found similar
reciprocation (same references) in teratoma. However, these
assumed correlations between the immunohistochemical and the
serological findings have yet to be confirmed by concomitantly
performing both essays. In our four main tumour groups
comprising nephroblastoma, neuroblastoma, retinoblastoma and
rhabdomyosarcoma, within the 60 cases of childhood embryonic
tumours, we found prominent HbF expression in up to 80% of
Table 3 The distribution of F-cells detected immunohistochemically in retinoblastoma patients
No Gender Age (years) F-cells features (1) Checked in tumour tissues Staining grade
1 Male 1 In BV, 50–100% Fc, 20–50% of them Feb. Proliferation of such BV and of free Fer,Feb clusters.
Congestions of Fc in haemorrhagic regions. Some Feb in mitosis, or as binucleated.
(+++)
2 Male 1 Same as above (+++++)
3 Male 1 Same as above (+++++)
4 Male 2 Same as above (+++++)
5 Male 1 BV PBV TC
Fer++ ( ) Fer (+++++)
6 Male 1/12 Fer++ ( ) Fer,Feb (++++)
7 Female 4 Fer+ ( ) Feb (+++++)
8 Female 1 No Fc ( ) Feb (+++++)
9 Male 11 ( ) Fer+ No Fc (+++)
10 Male 2 No Fc ( ) Feb (+)
11 Female 5 No Fc ( ) Feb (++)
12–14 1 Male 2 female 1, 2, 4 No Fc ( )
15 Female 4 (2) Checked in bone marrow
Clusters of Fc , predominantly Feb, throughout the whole section.
(+++++)
16 Female 3 Same as above (+++++)
17 Female 4 Same as above (+++++)
18 Male 3 No Fc ( )
Abbreviations: ( ), tissue not present in section; BV, blood vessels; Feb, Fblasts; Fc, F-cells; Fer, F-erythrocytes; Fer+, low percent of Fer; Fer++, high percent of Fer; PBV,
proliferating blood vessels; TC, tumour tissue.
Table 4 The distribution of F-cells immunohistochemically detected in rhadomyosarcoma
F-cells features (1) Checked tumour tissues
No. Gender
Age
(years) Tumour type BV PBV TC Staining grade
1 Female 2 Alveolar ( ) Fer,Feb++ Fer,Feb (+++++)
2 Female 3 Embryonal Fer++ ( ) No Fc (++++)
3 Female 4 Alveolar Fer++ ( ) Fer (++++)
4 Male 1 Embryonal Fer++ ( ) No Fc (+++++)
5 Female 5 Embryonal ( )(  ) Fer,Feb (++++)
6 Female 30 Embryonal Fer+ ( ) No Fc (++++)
7 Male 51 Embryonal Fer+ ( )N o F c ( + + )
8 Male 8 Embryonal ( )(  ) Fer (+)
9 Male 3 Embryonal. Chemt(+) No F-cells ( )
10 Male 13 (2) Checked in bone marrow clusters of infiltrating Fc, mainly Fer, throughout the whole section (+++++)
11 Female 6 Clusters of infiltrating Fc, mainly Feb, some Feb in mitosis (+++++)
12 Female 11 Mets to bone marrow No Fc ( )
13 Female 25 Same as above No Fc ( )
14 Male 2 No Fc ( )
Abbreviations: ( ), tissue not present in section; BV, blood vessels; Fc, F-cells; Feb, F-blasts; Fer, F-erythrocytes; Fer+, low percent of Fer; Fer++, high percent of Fer; PVB,
proliferating blood vessels; TC, tumour tissue.
Table 5 The distribution of F-cells immunohistochemically detected in
medulloblastoma of the cerebellum
F-cells features
No. Gender Age (years) BV TC Staining grade
1 Female 12 Fer++ Fer (+++)
2 Female 11 Fer+ Fer (+++)
3 Female 48 Fer (+++)
4 Female 35 Fer++ Feb (+++)
5 Male 26 ( ) Fer (+)
6 Female 5 ( ) Feb (+)
7 Female 5 No Fc ( )
8 Male 26 No Fc ( )
9 Male 26 No Fc ( )
10 Female 27 No Fc ( )
11 Female 15 Bone marrow with no Fc ( )
Abbreviations: ( ), tissue not present in section; BV, blood vessels; Fc, F-cells; Feb,
F-erythroblasts; Fer, F-erythrocytes; Fer+, low percent of Fer; Fer++, high percent
of Fer.
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spatients. This is the highest percentage of HbF ever detected
immunohistochemically in cancer, which makes it an important
feature of childhood embryonic tumour. Foetal haemoglobin
measurements should therefore be considered in the management
of those tumours, as the concentrations might change with
regression or progression of the tumours. Foetal haemoglobin
blood cells, most of them being Feb, were detected predominantly
in the bone marrow of patients with leukaemia, but also in
neuroblastoma, rhabdomyosarcoma, hapatoblastoma and espe-
cially in retinoblastoma. Since bone marrow is the likely source for
circulating Fc, its Fc-immunohistochemical evaluation could be an
early sign for the onset of those diseases, as for example in
childhood leukaemia where HbF has already been proved as a
prognostic marker (Rautonen and Siimes, 1990). In those cases the
examination of bone marrow is advantageous over other tissue
examinations, because sampling bone marrow aspirates is easier
than collecting biopsies or resected specimens. In our introduc-
tion, we noted the possible association between the HbF gene
reactivation and DNhpom implicated in oncogenesis. A support
for this association is found in the recent literature noting the
importance of DNhpom in embryonic tumours, found here to
contain high concentration of F-cells, including nephroblastoma
(Mares et al, 2001) and neuroblastoma (Banelli et al, 2005).
However, DNhpom is not always involved in the mechanisms of
reactivation HbF gene re-expression in cancer. There are yet other
hypothetical pathways not involving DNhpom. For example the
involvement of hydroxyurea – an important drug for inducing HbF
biosynthesis (Atweh et al, 2003), which like DNA demethylation
agents may promotes carcinogenesis (De Benedittis et al, 2004).
Another aspect of the abundance of F-cells inside these tumours
is related to their embryonic characteristics. Some of these
tumours mimic normal embryonic development, such as three-
phase nephroblastoma, containing mesenchyme, tubular and
glomerular elements, or neuroblastoma cells, which may differ-
entiate to ganglion cells or neural cells. It is therefore possible that
these tumours are programmed for autonomous foetal haemato-
poiesis by F-cell precursors. This hypothesis is supported by the
finding of HbF erythroblasts (Feb), some of them in mitosis, in all
of these embryonic tumours, most prominently in retinoblastoma
and nephroblastoma. Another support for Fc development in
tumour tissue comes from the finding of Fc, including Feb, in
proliferating blood vessels. These Fc were found only in the
tumour and not in other adjacent tissues like normal kidney tissue
adjacent to nephroblastoma (Table 1), or brain tissue adjacent to
glioblastoma, and neuroblastoma (Table 2, number 6; Figure 3A).
It seems thus that local regeneration rather than transportation
through the general circulation is the source of Fc among tumour
cells, and in proliferating blood vessels inside the tumours.
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